Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Keli Walbert currently holds 36,000 shares of Hemab Therapeutics Holdings, Inc. (COAG), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Keli Walbert has been a net neutral trader of COAG stock. They have purchased $0 and sold $0 worth of shares.
Keli Walbert's most recent insider trade was on Sep 24, 2026, when they sold 36,000 shares at $0.00 per share.
Keli Walbert serves as Executive at Hemab Therapeutics Holdings, Inc. (COAG). They have executed 1 insider transactions totaling $0 over their tenure at the company.
Keli Walbert holds the position of Executive at Hemab Therapeutics Holdings, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 1 years and currently hold a stake valued at $0.
Keli Walbert has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Keli Walbert was on Sep 24, 2026, when they purchased $0 worth of COAG shares. This transaction involved 36,000 shares at N/A per share.
Keli Walbert currently owns 36,000 shares of Hemab Therapeutics Holdings, Inc. (COAG), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Keli Walbert's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Keli Walbert has 1 Form 4 filings on record as an insider at Hemab Therapeutics Holdings, Inc..
Set alerts for Keli Walbert and 40,000+ other insiders.